Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylphenidate on Cognitive Parameters of Motivation
NCT03190681Phase 1Completed
- Sponsor
- Inserm
- Start
- Jul 2017
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of methylphenidate hydrochloride extended-release chewable tablet in apathy (2 arms), sponsored by Inserm. Primary endpoint: Coefficient of sensitivity to reward at 2 hours. Started Jul 2017; status: completed.
02
Drugs
methylphenidate hydrochloride extended-release chewable tablet
03
Conditions
apathy
Beyond the preview
Go deeper on NCT03190681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03190681.